Szukaj

54 Result(s)
Sortuj według

Our Commitment

Our Commitment

We want to create value in areas of unmet medical need and engage with communities and society to improve lives – for humans and animals.
Antibody therapeutics business partnering PetMedix

Antibody therapeutics business partnering PetMedix

Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
Performance Indicators

Performance Indicators

Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
BI Access to Healthcare Strategy_Availability

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Our Innovation Strategy

Our Innovation Strategy

Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.
Our Partners Harvard

Our Partners Harvard

Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
Advancing regenerative medicine

Advancing regenerative medicine

Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Our-position

Our-position

Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Behind the Lab

Behind the Lab

Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Women in STEM 2022

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Championing novel science

Championing novel science

Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.